Answers are grounded in this paper and cite their sources.
bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.
No takes yet. Share an insight, caveat, or question.
Mattesini et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: